Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors

Shoukou Lee, Chihiro Shinji, Kiyoshi Ogura, Motomu Shimizu, Satoko Maeda, Mayumi Sato, Minoru Yoshida, Yuichi Hashimoto, Hiroyuki Miyachi

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

We designed and synthesized hydroxamic acid derivatives bearing a 4-(3-pyridyl)phenyl group as a cap structure, and found that they exhibit potent histone deacetylase (HDAC) inhibitory activity. A representative compound, 17a, showed more potent growth-inhibitory activity against pancreatic cancer cells and greater upregulation of p21WAF1/CIP1 expression than the clinically used HDAC inhibitor suberoylanilide hydroxamic acid (Zolinza™).

Original languageEnglish
Pages (from-to)4895-4900
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Volume17
Issue number17
DOIs
Publication statusPublished - Sep 1 2007

Keywords

  • HDAC
  • HDAC inhibitor
  • Hydroxamic acid
  • Isoindoklinone
  • Pancreatic cancer
  • p21

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors'. Together they form a unique fingerprint.

  • Cite this

    Lee, S., Shinji, C., Ogura, K., Shimizu, M., Maeda, S., Sato, M., Yoshida, M., Hashimoto, Y., & Miyachi, H. (2007). Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Bioorganic and Medicinal Chemistry Letters, 17(17), 4895-4900. https://doi.org/10.1016/j.bmcl.2007.06.038